Contribution to rabies prevention.
After the end of the Second World War, an outbreak of fox rabies invaded Europe. For the immunization of human populations and domestic animals against the risk of rabies transmitted by infected wild animals, it appeared necessary to replace the first generation of rabies vaccines (nerve tissue vaccines) by more potent and safer vaccines. The European vaccine manufacturers, in close collaboration with the research institutes engaged in rabies research, soon and quickly developed a second generation of rabies vaccines, produced in cell cultures including continuous cell lines grown in bioreactors of industrial scale. The third generation of rabies vaccines is already available: the vaccinia-rabies glycoprotein recombinant vaccine is presently applied on a large scale in some European countries for immunization of wildlife. The canarypox recombinant vaccine has already been considered and successfully tested for human immunization.
Sureau
P
P
Institut Pasteur, Paris, France.
D000284:Administration, Oral; D000818:Animals; D000829:Animals, Domestic; D000835:Animals, Wild; D002460:Cell Line; D003132:Commerce; D003906:Developing Countries; D004196:Disease Outbreaks; D004283:Dog Diseases / Q000453:epidemiology / Q000517:prevention & control; D004285:Dogs; D004345:Drug Industry; D005060:Europe / Q000453:epidemiology; D005589:Foxes / Q000382:microbiology; D006801:Humans; D011818:Rabies / Q000453:epidemiology / Q000517:prevention & control* / Q000662:veterinary; D011819:Rabies Vaccines / Q000145:classification / Q000600:supply & distribution; D014611:Vaccination / Q000706:statistics & numerical data
D011819:Rabies Vaccines